BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq: SGEN) today announced the appointment of James Kyle Bryan, M.D., as Vice President, Medical Affairs. Dr. Bryan is a hematologist and medical oncologist, and brings more than 18 years of experience in oncology drug development. In addition, the company announced the promotion of Charles Smith to Vice President, Quality. Mr. Smith joined Seattle Genetics in 2003, and has played a key leadership role in the company’s Technical Operations group, including successful regulatory inspections to support the recent U.S. Food and Drug Administration approval of ADCETRIS™ (brentuximab vedotin).
